Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials.

van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, Benatar M, Berry JD, Chio A, Corcia P, Genge A, Gubitz AK, Lomen-Hoerth C, McDermott CJ, Pioro EP, Rosenfeld J, Silani V, Turner MR, Weber M, Brooks BR, Miller RG, Mitsumoto H; Airlie House ALS Clinical Trials Guidelines Group.

Neurology. 2019 Mar 8. pii: 10.1212/WNL.0000000000007242. doi: 10.1212/WNL.0000000000007242. [Epub ahead of print]

PMID:
30850440
2.

Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.

Hodgkinson VL, Lounsberry J, Mirian A, Genge A, Benstead T, Briemberg H, Grant I, Hader W, Johnston WS, Kalra S, Linassi G, Massie R, Melanson M, O'Connell C, Schellenberg K, Shoesmith C, Taylor S, Worley S, Zinman L, Korngut L.

Can J Neurol Sci. 2018 Nov;45(6):652-659. doi: 10.1017/cjn.2018.311.

PMID:
30430962
3.

Relationships between slow vital capacity and measures of respiratory function on the ALSFRS-R.

Jackson C, De Carvalho M, Genge A, Heiman-Patterson T, Shefner JM, Wei J, Wolff AA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Oct 31:1-7. doi: 10.1080/21678421.2018.1497658. [Epub ahead of print]

PMID:
30379086
4.

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.

Hughes R, Dalakas MC, Merkies I, Latov N, Léger JM, Nobile-Orazio E, Sobue G, Genge A, Cornblath D, Merschhemke M, Ervin CM, Agoropoulou C, Hartung HP; FORCIDP Trial Investigators.

Lancet Neurol. 2018 Aug;17(8):689-698. doi: 10.1016/S1474-4422(18)30202-3. Epub 2018 Jul 9. Erratum in: Lancet Neurol. 2018 Nov;17(11):933.

PMID:
30001923
5.

A Preliminary Videofluoroscopic Investigation of Swallowing Physiology and Function in Individuals with Oculopharyngeal Muscular Dystrophy (OPMD).

Waito AA, Steele CM, Peladeau-Pigeon M, Genge A, Argov Z.

Dysphagia. 2018 Dec;33(6):789-802. doi: 10.1007/s00455-018-9904-9. Epub 2018 May 3.

PMID:
29725764
6.

Understanding the use of NIV in ALS: results of an international ALS specialist survey.

Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):331-341. doi: 10.1080/21678421.2018.1457058. Epub 2018 Apr 16.

PMID:
29661084
7.

Respiratory measures in amyotrophic lateral sclerosis.

Lechtzin N, Cudkowicz ME, de Carvalho M, Genge A, Hardiman O, Mitsumoto H, Mora JS, Shefner J, Van den Berg LH, Andrews JA.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):321-330. doi: 10.1080/21678421.2018.1452945. Epub 2018 Mar 23. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):478.

PMID:
29566571
8.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group.

Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28.

9.

Hair product artifact in magnetic resonance imaging.

Chenji S, Wilman AH, Mah D, Seres P, Genge A, Kalra S.

Magn Reson Imaging. 2017 Jan;35:1-3. doi: 10.1016/j.mri.2016.08.023. Epub 2016 Aug 30.

PMID:
27590880
10.

Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel.

Tarnopolsky M, Katzberg H, Petrof BJ, Sirrs S, Sarnat HB, Myers K, Dupré N, Dodig D, Genge A, Venance SL, Korngut L, Raiman J, Khan A.

Can J Neurol Sci. 2016 Jul;43(4):472-85. doi: 10.1017/cjn.2016.37. Epub 2016 Apr 8. Review.

PMID:
27055517
11.

Reevaluating Muscle Biopsies in the Diagnosis of Pompe Disease: A Corroborative Report.

Genge A, Campbell N.

Can J Neurol Sci. 2016 Jul;43(4):561-6. doi: 10.1017/cjn.2016.29. Epub 2016 Apr 4.

PMID:
27039993
12.

Feasibility of Lung Volume Recruitment in Early Neuromuscular Weakness: A Comparison Between Amyotrophic Lateral Sclerosis, Myotonic Dystrophy, and Postpolio Syndrome.

Kaminska M, Browman F, Trojan DA, Genge A, Benedetti A, Petrof BJ.

PM R. 2015 Jul;7(7):677-684. doi: 10.1016/j.pmrj.2015.04.001. Epub 2015 Apr 3.

PMID:
25845857
13.

A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement.

Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, Simpson E, Genge A, Bertorini T, Fernandes JA, Swenson A, Elman L, Dimachkie M, Herbelin L, Miller J, Lu J, Wilkins H, Swerdlow RH, Statland J, Barohn R; Western ALS (WALS) Rasagiline Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):345-52. doi: 10.3109/21678421.2015.1026826. Epub 2015 Apr 2.

14.

The Search for Pompe Patients in Canada: Assessing Feasibility of a National Disease Registry to Facilitate Research.

Korngut L, Johnston M, Campbell C, Genge A, MacKenzie A, McCormick A, Venance S.

J Neuromuscul Dis. 2015;2(s1):S45-S46. No abstract available.

PMID:
27858639
15.

Screening for Pompe Disease in Specific At-Risk Populations with Sleep-Disordered Breathing.

Kaminska M, Noel F, Genge A, Melancon SB, Pshezhetsky A, Petrof BJ.

J Neuromuscul Dis. 2015;2(s1):S44. No abstract available.

PMID:
27858638
16.

Validation and interpretation of neurological registry data.

Pringsheim T, Lam D, Day L, Genge A, Hogan DB, Shevell M, Fortin CM, Maxwell C, Fiebelkorn G, Barlow K, Kapral MK, Casha S, Mobach T, Johnston M, Jette N, Korngut L.

Can J Neurol Sci. 2013 Jul;40(4 Suppl 2):S51-3. Review. No abstract available.

PMID:
23787269
17.

Patient recruitment by neurological registries.

Hamilton M, Genge A, Johnston M, Lam D, Mobach T, Marriott J, Steeves T, Donner E, Wysocki J, Barlow K, Shevell M, Marrie RA, Casha S, Mackean G, Casselman L, Korngut L, Pringsheim T, Jette N.

Can J Neurol Sci. 2013 Jul;40(4 Suppl 2):S23-6. Review. No abstract available.

PMID:
23787262
18.

The CNDR: collaborating to translate new therapies for Canadians.

Korngut L, Campbell C, Johnston M, Benstead T, Genge A, Mackenzie A, McCormick A, Biggar D, Bourque P, Briemberg H, O'Connell C, Dojeiji S, Dooley J, Grant I, Hogan G, Johnston W, Kalra S, Katzberg HD, Mah JK, McAdam L, McMillan HJ, Melanson M, Selby K, Shoesmith C, Smith G, Venance SL, Wee J; CNDR Investigator Network.

Can J Neurol Sci. 2013 Sep;40(5):698-704.

PMID:
23968944
19.

Establishing a Canadian registry of patients with amyotrophic lateral sclerosis.

Korngut L, Genge A, Johnston M, Benstead T, Bourque P, Briemberg H, Casey A, D'Amour M, Dupré N, Figlewicz D, Hader W, Johnston W, Kalra S, Melanson M, O'Connell C, Rouleau G, Shoesmith C, Wee J, Zinman L.

Can J Neurol Sci. 2013 Jan;40(1):29-35.

PMID:
23250124
20.

Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29.

Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupler E, Lou JS, Ensrud E, Tan E, Goldstein JM, Katz J, Dimachkie MM, Barohn RJ, Mozaffar T.

J Neuropathol Exp Neurol. 2011 Jan;70(1):96-7; author reply 98-100. doi: 10.1097/NEN.0b013e318204782b. No abstract available.

PMID:
21173608

Supplemental Content

Loading ...
Support Center